Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro

Leukemia and Lymphoma

Volumn 50, Issue 3, 2009, Pages 437-446

  Liu, He ^a   Li, Hongyan ^a   Feng, Zhiqiang ^a   Tai, Jun ^b   Meng, Yang ^a   Wang, Hongbo ^a   Xin, Hongqi ^a   Zhang, Sen ^a   Zuo, Mingxin ^a   Zhang, Yan ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Bcr Abl; Chronic myelogenous leukemia; Imatinib; Inhibitor; Resistance; Src

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; DASATINIB; IMATINIB; N (THIAZOL 2 YL)PYRIMIDIN 4 AMINE DERIVATIVE; PROTEIN KINASE LYN; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SURVIVAL TIME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, SCID; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SRC-FAMILY KINASES; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650928403     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802709438     Document Type: Article

References (43)

1. Rowley, J. D. (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, pp. 290-293.
2. de Klein, A., van Kessel, A. G., Grosveld, G., Bartram, C. R., Hagemeijer, A. Bootsma, D. et al. (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 300, pp. 765-767.
3. Buchdunger, E., Matter, A. and Druker, B. J. (2001) Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta, 1551, pp. M11-M18.
4. Hegedus, T., Orfi, L., Seprodi, A., Varadi, A., Sarkadi, B. and Keri, G. (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta, 1587, pp. 318-325.
5. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R. Rao, P. N. et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, pp. 876-880.
6. Hofmann, W. K., Jones, L. C., Lemp, N. A., de Vos, S., Gschaidmeier, H. Hoelzer, D. et al. (2002) Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood, 99, pp. 1860-1862.
7. Nardi, V., Azam, M. and Daley, G. Q. (2004) Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol, 11, pp. 35-43.
8. Deininger, M. W. and Holyoake, T. L. (2005) Can we afford to let sleeping dogs lie?. Blood, 105, pp. 1840-1841.
9. Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H. Arlinghaus, R. et al. (2003) BCR-ABL independence and LYN kinase over expression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 101, pp. 690-698.
10. Dai, Y., Rahmani, M., Corey, S. J., Dent, P. and Grant, S. (2004) A Bcr/ Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem, 279, pp. 34227-34239.
11. Cowan-Jacob, S. W., Guez, V., Fendrich, G., Griffin, J. D., Fabbro, D. Furet, P. et al. (2004) Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem, 4, pp. 285-299.
12. Tokarski, J. S., Newitt, J. A., Chang, C. Y., Cheng, J. D., Wittekind, M. Kiefer, S. E. et al. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res, 66, pp. 5790-5797.
13. Gambacorti-Passerini, C., Gasser, M., Ahmed, S., Assouline, S. and Scapozza, L. (2005) Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia, 19, pp. 1267-1269.
14. Nam, S., Kim, D., Cheng, J. Q., Zhang, S., Lee, J. H. Buettner, R. et al. (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res, 65, pp. 9185-9189.
15. Chen, Z., Lee, F. Y., Bhalla, K. N. and Wu, J. (2006) Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol, 69, pp. 1527-1533.
16. Qi, J., Peng, H., Gu, Z. L., Liang, Z. Q. and Yang, C. Z. (2004) Establishment of an imatinib resistant cell line K562/G01 and its characterization. Zhonghua Xue Ye Xue Za Zhi, 25, pp. 337-341.
17. Tringali, C., Lupo, B., Anastasia, L., Papini, N., Monti, E. Bresciani, R. et al. (2007) Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling. J Biol Chem, 282, pp. 14364-14372.
18. Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M. Schepartz, S. et al. (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer, 84, pp. 1424-1431.
19. Borowski, E., Bontemps-Gracz, M. M. and Piwkowska, A. (2005) Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol, 52, pp. 609-627.
20. Gottesman, M. M. (2002) Mechanisms of cancer drug resistance. Annu Rev Med, 53, pp. 615-627.
21. Endicott, J. A. and Ling, V. (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem, 58, pp. 137-171.
22. Marie, J. P., Faussat-Suberville, A. M., Zhou, D. and Zittoun, R. (1993) Daunorubicin uptake by leukemic cells: Correlations with treatment outcome and mdr1 expression. Leukemia, 7, pp. 825-831.
23. Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L. Kuriyan, J. et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2, pp. 117-125.
24. le Coutre, P, Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L. Cabrita, G. et al. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 95, pp. 1758-1766.
25. Nimmanapalli, R., O'Bryan, E., Huang, M., Bali, P., Burnette, P. K. Loughran, T. et al. (2002) Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res, 62, pp. 5761-5769.
26. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M. Druker, B. J. et al. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res, 56, pp. 100-104.
27. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S. Druker, B. J. et al. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther, 295, pp. 139-145.
28. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M. Fanning, S. et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2, pp. 561-566.
29. Demetri, G. D. (2002) Identification and treatment of chemoresistant inoperable or metastatic GIST: Experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer, 38, pp. S52-S59.
30. Donato, N. J., Wu, J. Y., Stapley, J., Lin, H., Arlinghaus, R. Aggarwal, B. B. et al. (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res, 64, pp. 672-677.
31. Danhauser-Riedl, S., Warmuth, M., Druker, B. J., Emmerich, B. and Hallek, M. (1996) Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res, 56, pp. 3589-3596.
32. Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C. Behnia, K. et al. (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem, 47, pp. 6658-6661.
33. Warmuth, M., Bergmann, M., Priess, A., Hauslmann, K., Emmerich, B. and Hallek, M. (1997) The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem, 272, pp. 33260-33270.
34. Klejman, A., Schreiner, S. J., Nieborowska-Skorska, M., Slupianek, A., Wilson, M. Smithgall, T. E. et al. (2002) The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J, 21, pp. 5766-5774.
35. Stanglmaier, M., Warmuth, M., Kleinlein, I., Reis, S. and Hallek, M. (2003) The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia, 17, pp. 283-289.
36. Lionberger, J. M., Wilson, M. B. and Smithgall, T. E. (2000) Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem, 275, pp. 18581-18585.
37. Wilson, M. B., Schreiner, S. J., Choi, H. J., Kamens, J. and Smithgall, T. E. (2002) Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene, 21, pp. 8075-8088.
38. Warmuth, M., Simon, N., Mitina, O., Mathes, R., Fabbro, D. Manley, P. W. et al. (2003) Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood, 101, pp. 664-672.
39. Chang, Y. M., Kung, H. J. and Evans, C. P. (2007) Nonreceptor tyrosine kinases in prostate cancer. Neoplasia, 9, pp. 90-100.
40. Fizazi, K. (2007) The role of Src in prostate cancer. Ann Oncol, 18, pp. 1765-1773.
41. Hiscox, S., Morgan, L., Green, T. and Nicholson, R. I. (2006) Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer, 13, pp. S53-S59.
42. Jackson, J. G., Yoneda, T., Clark, G. M. and Yee, D. (2000) Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. Clin Cancer Res, 6, pp. 1135-1139.
43. Slack, J. K., Adams, R. B., Rovin, J. D., Bissonette, E. A., Stoker, C. E. and Parsons, J. T. (2001) Alterations in the focal adhesion kinase/ Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene, 20, pp. 1152-1163.